Rosalind Advisors, Inc.
13F Reported Value
ⓘ$248.9M
incl. option notional
Equity Holdings
ⓘ$244.1M
Option Notional
ⓘ$4.8M
$2.1M puts / $2.7M calls
Holdings
38
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Rosalind Advisors, Inc. disclosed 38 positions worth $248.9M in its Form 13F-HR for Q1 2026 — $244.1M in common stock plus $4.8M of put/call option positions (reported at underlying notional value, not premium at risk), led by $DCTH (DELCATH SYSTEMS, INC.) at 12.6% of the equity portfolio, followed by $XERS and $FENC. During the quarter the fund opened 12 new positions and exited 16 — including a new stake in $PCVX and a full exit from $REPL. The portfolio is most concentrated in Healthcare (94.5% of disclosed assets). All figures are sourced directly from Rosalind Advisors, Inc.’s Form 13F-HR filing with the SEC under CIK 1622627.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 54.9#1,188
Quality
$30.6M3,300,389 sh - 45.5#1,714
Quality
$18.7M3,231,700 sh - 33.9#2,218
Quality
$17.9M2,908,201 sh - —
Quality
$17.5M3,203,721 sh - —
Quality
$16.9M290,000 sh - 10.3
Quality
$13.4M1,036,737 sh - 29.3
Quality
$13.3M3,214,766 sh - —
Quality
$12.5M700,000 sh - —
Quality
$12.1M749,054 sh - 40.8
Quality
$11.3M2,138,475 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 DELCATH SYSTEMS, INC.$DCTH | 54.9#1,188 | $30.6M | 3,300,389 |
 Xeris Biopharma Holdings, Inc.$XERS | 45.5#1,714 | $18.7M | 3,231,700 |
 FENNEC PHARMACEUTICALS INC.$FENC | 33.9#2,218 | $17.9M | 2,908,201 |
 Savara Inc$SVRA | — | $17.5M | 3,203,721 |
 Vaxcyte, Inc.$PCVX | — | $16.9M | 290,000 |
 EyePoint, Inc.$EYPT | 10.3 | $13.4M | 1,036,737 |
 X4 Pharmaceuticals, Inc$XFOR | 29.3 | $13.3M | 3,214,766 |
 Vor Biopharma Inc.$VOR | — | $12.5M | 700,000 |
 MediWound Ltd.$MDWD | — | $12.1M | 749,054 |
 Verastem, Inc.$VSTM | 40.8 | $11.3M | 2,138,475 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Rosalind Advisors, Inc.'s 38 positions.
Showing top 10 of 38 holdings.
Sector Allocation
Healthcare
$230.7M
Technology
$13.4M
Full Holdings — Rosalind Advisors, Inc. (Q1 2026)
All 38 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $DCTH | DELCATH SYSTEMS, INC. | $30.6M | 12.6% | +0% | 54.9 |
| 2 | $XERS | Xeris Biopharma Holdings, Inc. | $18.7M | 7.7% | +53% | 45.5 |
| 3 | $FENC | FENNEC PHARMACEUTICALS INC. | $17.9M | 7.3% | +11% | 33.9 |
| 4 | $SVRA | Savara Inc | $17.5M | 7.2% | -6% | — |
| 5 | $PCVX | Vaxcyte, Inc. | $16.9M | 6.9% | NEW | — |
| 6 | $EYPT | EyePoint, Inc. | $13.4M | 5.5% | +50% | 10.3 |
| 7 | $XFOR | X4 Pharmaceuticals, Inc | $13.3M | 5.4% | +23% | 29.3 |
| 8 | $VOR | Vor Biopharma Inc. | $12.5M | 5.1% | NEW | — |
| 9 | $MDWD | MediWound Ltd. | $12.1M | 4.9% | +0% | — |
| 10 | $VSTM | Verastem, Inc. | $11.3M | 4.6% | +20% | 40.8 |
| 11 |  $CLDX | Celldex Therapeutics, Inc. | $10.5M | 4.3% | NEW | 13.2 |
| 12 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $8.8M | 3.6% | NEW | 37.2 |
| 13 |  $HELP | CYBIN INC. | $7.4M | 3.0% | -8% | — |
| 14 |  $CGON | CG Oncology, Inc. | $6.8M | 2.8% | -67% | 28 |
| 15 |  $NSPR | InspireMD, Inc. | $6.4M | 2.6% | +0% | — |
| 16 |  $AVIR | Atea Pharmaceuticals, Inc. | $6.3M | 2.6% | NEW | — |
| 17 |  $PROF | Profound Medical Corp. | $5.4M | 2.2% | -23% | — |
| 18 |  $VRDN | Viridian Therapeutics, Inc.\DE | $4.9M | 2.0% | -44% | 30.5 |
| 19 |  $REPLCALL | Replimune Group, Inc. | $2.7M | — | +452% | — |
| 20 |  $PYPD | PolyPid Ltd. | $2.6M | 1.1% | -14% | — |
| 21 |  $MYO | MYOMO, INC. | $2.6M | 1.1% | +0% | 27.9 |
| 22 |  $TLPH | TALPHERA, INC. | $2.5M | 1.0% | -6% | — |
| 23 |  $OVID | Ovid Therapeutics Inc. | $2.5M | 1.0% | NEW | 13.1 |
| 24 |  $DFTX | Definium Therapeutics, Inc. | $2.4M | 1.0% | NEW | — |
| 25 |  $OKUR | OnKure Therapeutics, Inc. | $1.8M | 0.8% | -39% | — |
| 26 |  $LPCN | Lipocine Inc. | $1.8M | 0.7% | NEW | — |
| 27 |  $NRXS | Neuraxis, INC | $1.7M | 0.7% | +0% | — |
| 28 |  $AVTX | Avalo Therapeutics, Inc. | $1.1M | 0.5% | NEW | 4.6 |
| 29 |  $ANNX | Annexon, Inc. | $1.1M | 0.5% | NEW | — |
| 30 |  $QQQPUT | INVESCO QQQ TRUST, SERIES 1 | $1.1M | — | -44% | — |
| 31 |  $AQST | Aquestive Therapeutics, Inc. | $1.0M | 0.4% | NEW | 11.7 |
| 32 |  $SPYPUT | SPDR S&P 500 ETF TRUST | $958,500 | — | -75% | — |
| 33 |  $BFRI | Biofrontera Inc. | $941,645 | 0.4% | +2% | 21.3 |
| 34 |  $KURA | Kura Oncology, Inc. | $813,000 | 0.3% | +0% | 9.1 |
| 35 |  $RGNT | REGENTIS BIOMATERIALS LTD. | $768,363 | 0.3% | +0% | — |
| 36 | $VRDNPUT | Viridian Therapeutics, Inc.\DE | $52,720 | — | NEW | 30.5 |
| 37 |  $QURECALL | uniQure N.V. | $0 | — | +196% | — |
| 38 |  $AVBPCALL | ArriVent BioPharma, Inc. | $0 | — | +1% | — |
New Positions (12)
$PCVX Vaxcyte, Inc.$16.9M$VOR Vor Biopharma Inc.$12.5M$CLDX Celldex Therapeutics, Inc.$10.5M$BCRX BIOCRYST PHARMACEUTICALS INC$8.8M$AVIR Atea Pharmaceuticals, Inc.$6.3M$OVID Ovid Therapeutics Inc.$2.5M$DFTX Definium Therapeutics, Inc.$2.4M$LPCN Lipocine Inc.$1.8M$AVTX Avalo Therapeutics, Inc.$1.1M$ANNX Annexon, Inc.$1.1M$AQST Aquestive Therapeutics, Inc.$1.0M$VRDNPUT Viridian Therapeutics, Inc.\DE$52,720Exited Positions (16)
$REPL Replimune Group, Inc.
$ATYR aTYR PHARMA INC
$CYTK CYTOKINETICS INC
$OCUL OCULAR THERAPEUTIX, INC$AVBP ArriVent BioPharma, Inc.
$AVXLPUT ANAVEX LIFE SCIENCES CORP.
$TRVI Trevi Therapeutics, Inc.
$GUTS FRACTYL HEALTH, INC.$VSTMCALL Verastem, Inc.
$VKTXCALL Viking Therapeutics, Inc.$REPLPUT Replimune Group, Inc.
$RZLTCALL Rezolute, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Rosalind Advisors, Inc. including:
Track Rosalind Advisors, Inc.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Rosalind Advisors, Inc. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Rosalind Advisors, Inc.
13F Pro is an AI hedge fund tracker and stock research platform. For Rosalind Advisors, Inc. (SEC CIK: 1622627), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Rosalind Advisors, Inc.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.